How GLP-1 & GLP-1/GIP Therapies Differ

A GLP-1 receptor agonist is a medication that acts on a hormone pathway involved in appetite and glucose regulation. Semaglutide is one medication in this category. Tirzepatide acts on both the GIP receptor and GLP-1 receptor pathways.

FDA-approved semaglutide and tirzepatide weight-management labeling describes their use alongside a reduced-calorie diet and increased physical activity for eligible patients. That category-level information doesn’t establish that every peptide formulation, ingredient combination, or route of administration has the same approval status or clinical evidence.

Individual response can depend on the specific medication, dose, treatment duration, side effects, adherence, and long-term maintenance plan. A result reported in a clinical study isn’t a promise of an individual outcome.

Candidacy for Medical Weight Management

Candidacy requires an individual medical evaluation. FDA-approved medications for chronic weight management commonly use body mass index (BMI) of 30 or higher or 27 or higher with at least one weight-related medical condition as part of their eligibility criteria.

A provider may also review your medical history, current medications, prior weight-management attempts, and potential contraindications. Meeting the criteria for one FDA-approved medication doesn’t establish suitability for every peptide formulation or oral or injectable option.

Information that may be relevant to an evaluation includes:

• Current medications and supplements
• Weight-related medical conditions
• Previous weight-management treatments
• Pregnancy or plans for pregnancy
• Medication allergies or prior adverse reactions
• Preferred route of administration

Side Effects, Dosing & Compounded Products

Medication side effects vary by product and patient. FDA-approved semaglutide labeling reports reactions that can include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, and other gastrointestinal symptoms.

FDA-approved drugs and compounded preparations are different. Compounded semaglutide and tirzepatide products aren’t reviewed by the FDA for safety, effectiveness, or quality before marketing. The FDA has also reported dosing errors involving compounded injectable semaglutide, including confusion among milligrams, milliliters, units, concentrations, and multi-dose vials.

The FDA states that the safety and effectiveness of combining semaglutide with ingredients such as vitamin B12, L-Carnitine, or NAD+ haven’t been established. Before beginning treatment, ask the treating clinician to identify the formulation and source, explain the dosing instructions, review medication interactions and pregnancy considerations, and describe what to do if side effects occur.

Discuss Your Options in a Free Consultation

A free consultation is the next step toward determining whether peptide weight loss treatment fits your goals and health circumstances. A member of our team can contact you to confirm the details and answer your questions.

Call (336) 600-9259 to request your free consultation with NuBody Solutions.